FDA May Allow 'Mix and Match' Regime For COVID-19 Booster Shots: NYT - Johnson & Johnson (NYSE:JNJ), Moderna (NASDAQ:MRNA)

The FDA is planning to allow Americans to get a different booster shot of a COVID-19 vaccine than the one initially taken, the New York Times reported.
The move could potentially reduce the appeal of the Johnson & Johnson JNJ vaccine and provide flexibility to doctors and other vaccinators.
The government would not recommend one shot over another, and it might note that using the same vaccine as a booster when possible is preferable, the NYT report said, citing people familiar with the agency's plans.
The researchers presented the findings of a federally funded "mix and match" study.
Related: NIH-Backed US Study Of Mixed COVID-19 Vaccines Regime To Conclude Soon: CNBC.
The study found that recipients of Johnson & Johnson's single-dose shot who received a Moderna Inc MRNA booster saw their antibody levels rise 76-fold in 15 days, compared with a fourfold increase after the JNJ booster.
The FDA is expected to authorize boosters of the Moderna and Johnson & Johnson vaccines by Wednesday.
Related: Johnson & Johnson's COVID-19 Booster Dose Wins FDA Adcomm Backing.
Price Action: JNJ shares traded 0.39% lower at $159.50, and MRNA shares are up 2.50% at $343.20 during the premarket session on the last check Tuesday.
Photo by Johaehn from Pixabay